Current Issue
Vol.12 No.3, December 20, 2024
-
Review Article | 2024-12-20
59
26
식도편평상피암의 내시경 점막하 박리술 치료
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma
김윤아
Journal of Digestive Cancer Research 2024; 12(3): 145-152 https://doi.org/10.52927/jdcr.2024.12.3.145Abstract : Endoscopic submucosal dissection (ESD) is a predominantly used technique for superficial esophageal cancer treatment. The primary advantages of esophageal ESD include its high en bloc resection rate and the precise pathological assessment it confers. This procedure enables local primary tumor resection while accurately assessing risk factors for lymph node metastasis, including tumor depth, vascular invasion, and invasion type. Esophageal ESD will play a crucial role in minimally invasive and effective esophageal cancer treatments. In this article we discuss esophageal ESD regarding its indications, treatment outcomes, techniques, potential complications, and follow-up guidelines to ensure its safe and effective application.
-
Review Article | 2024-12-20 73
21
위암에서의 로봇위절제술: 수술 후 단기 성적 및 장기 종양학적 안정성 검토
Robotic Gastrectomy for Gastric Cancer: A Review of Postoperative and Oncologic Outcomes
김유민
Journal of Digestive Cancer Research 2024; 12(3): 153-159 https://doi.org/10.52927/jdcr.2024.12.3.153Abstract : Robotic gastrectomy is a promising alternative to laparoscopic surgery for gastric cancer. This review examines the indications and the short-term surgical and long-term oncologic results of robotic gastrectomy. The indications for robotic gastrectomy have evolved in parallel to those for laparoscopic gastrectomy, with D1+ lymphadenectomy performed for early gastric cancer and D2 lymphadenectomy reserved for advanced gastric cancer. Regarding short-term outcomes, robotic gastrectomy is associated with less intraoperative blood loss, and longer operation times, compared with laparoscopic gastrectomy. Mortality and overall complication rates are similar between the two approaches, although robotic gastrectomy has been associated with lower rates of severe complications requiring surgical intervention or intensive care unit admission as well as infectious complications, such as anastomotic leakage, pancreatic fistula, and intraabdominal abscess. Long-term oncologic outcomes, including overall and disease-free survival and recurrence rates, were comparable between robotic and laparoscopic surgeries. Despite the associated high cost, the potential of robotic gastrectomy is expected to be realized with the recent introduction of various robotic surgical systems, which should aid in resolving cost concerns through market competition. Furthermore, the development of new evaluation tools that can objectively assess ergonomic benefits and surgeon fatigue should demonstrate the practical value of robotic surgery in the treatment of gastric cancer.
-
Review Article | 2024-12-20 68
25
Post-colonoscopy Colorectal Cancer: Causes and Prevention
Jong Yoon Lee
Journal of Digestive Cancer Research 2024; 12(3): 160-170 https://doi.org/10.52927/jdcr.2024.12.3.160
Abstract : Post-colonoscopy colorectal cancer (PCCRC), classified as colorectal cancer (CRC) diagnosed following a negative colonoscopy and prior to the recommended follow-up; despite advancements in the quality of colonoscopy, remains a significant concern. PCCRC accounts for 1.8 to 9.0% of CRC cases globally and 6.2% CRC cases in Korea. The predominant reasons for the incidence of PCCRC include procedural factors such as missed lesions and incomplete resections, and newly developed lesions. Few strategies that can mitigate PCCRC include improving adenoma detection rates to at least 25 to 35%, ensuring withdrawal times of ≥ 8 minutes, adequate bowel preparation, and cecal intubation rates exceeding 90 to 95%. For preventing PCCRC, advanced imaging technologies and enhanced polypectomy techniques, such as en bloc resection for larger or potentially malignant polyps are critical. This review highlights the multifactorial nature of PCCRC and the significance of quality assurance in colonoscopy for reducing its prevalence.
-
Review Article | 2024-12-20 57
40
Carbohydrate Antigen 19-9 상승에 대한 현실적 접근
Realistic Approach to Elevated Carbohydrate Antigen 19-9
정한택, 한지민
Journal of Digestive Cancer Research 2024; 12(3): 171-175 https://doi.org/10.52927/jdcr.2024.12.3.171
Abstract : Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker initially identified from colorectal cancer cell lines and is currently widely used in the diagnosis and monitoring of pancreatic and biliary tract cancers. Although CA 19-9 is not routinely screened in general checkups, increasing its screening has led to the frequent detection of elevated CA 19-9 levels in asymptomatic individuals. Patients with elevated CA 19-9 levels often visit clinics for concerns about malignancy, making cancer exclusion essential to exclude cancers through detailed medical history taking, physical examination, and imaging studies. However, many cases of elevated CA 19-9 levels result from benign causes, such as pancreatobiliary diseases, hepatic diseases, pulmonary diseases, or gynecologic conditions. Thus, to avoid unnecessary tests, clinicians must understand the various causes and mechanisms of CA 19-9 elevation. Integrating the patient’s symptoms and medical and family history facilitates appropriate test selection and minimizes unnecessary procedures.
-
Review Article | 2024-12-20 46
40
담도암 면역치료 및 표적치료의 최신 지견과 전망
Recent Advances in Immunotherapy and Targeted Therapy for Biliary Tract Cancer
이정욱1, 강화평2
Journal of Digestive Cancer Research 2024; 12(3): 176-183 https://doi.org/10.52927/jdcr.2024.12.3.176Abstract : Biliary tract cancer (BTC) is a rare malignancy with increasing incidence and mortality over the past two decades. Despite its unique anatomical and molecular features, BTC is typically diagnosed at advanced stages, thereby limiting treatment options and resulting in poor prognosis. Recent advances in molecular profiling and immunotherapy have revolutionized the BTC management, illustrating its molecular and immunologic underpinnings. Immune checkpoint inhibitors such as durvalumab and pembrolizumab, when combined with gemcitabine/ cisplatin, provide considerable survival benefits, with phase 3 trials such as TOPAZ-1 and KEYNOTE-966 demonstrating improved overall and progression-free survivals with immune checkpoint inhibitors compared to the conventional gemcitabine/cisplatin therapy. Therapies targeting FGFR2 fusions, IDH1 mutations, and HER2 overexpression have further expanded the therapeutic landscape, offering precision medicine opportunities for patients with actionable mutations. However, challenges persist owing to the rarity of BTC and inherent limitations of small cohort studies. Future research should focus on large, multicenter, prospective trials, establish new treatment paradigms, and expand therapeutic applications. In addition, integrating next-generation sequencing into routine practice will enhance molecular-based treatment approaches. This review explores the latest advancements in BTC immunotherapy and targeted therapies, emphasizing their clinical applicability in improving patient outcomes.
-
Review Article | 2024-12-20 42
21
Metabolic Dysfunction-associated Steatotic Liver Disease–related Hepatocellular Carcinoma: Current Research Insights
Ho Soo Chun
Journal of Digestive Cancer Research 2024; 12(3): 184-194 https://doi.org/10.52927/jdcr.2024.12.3.184, Minjong Lee , Tae Hun Kim Abstract : The global increase in the incidence of metabolic disorders is increasing the burden of nonalcoholic fatty liver disease (NAFLD) progression and NAFLD-related hepatocellular carcinoma (HCC) development; urgent measures are required to reduce this burden. The metabolic aspects of NAFLD led to the proposal to rename this condition as metabolic dysfunction-associated steatotic liver disease (MASLD). Diagnosis of MASLD, unlike that of NAFLD, requires the presence of at least one cardiometabolic risk factor (CMRF), creating a new focus on these factors, although the vast majority of patients with NAFLD meet the criteria for MASLD. In this article, we therefore review the current understanding of MASLD-related HCC, such as the epidemiology, risk factors with a particular focus on CMRFs, surveillance strategies, and risk stratification models.
-
Review Article | 2024-12-20 58
22
항암 치료를 받는 환자의 치과적 고려사항
Dental Considerations for Patients Undergoing Chemotherapy
강은숙
Journal of Digestive Cancer Research 2024; 12(3): 195-206 https://doi.org/10.52927/jdcr.2024.12.3.195Abstract : Even with the advances in chemotherapeutic procedures and agents, chemotherapy may cause certain side effects that impair patients’ quality of life. Cancer treatment can lead to various other side effects, such as xerostomia, mucositis, dental caries, opportunistic infections, hypogeusia, dysgeusia, hyposalivation, and medication-related osteonecrosis of the jaw. The oral cavity is a common site of discomfort and pain caused by chemotherapy. In this paper, I will discuss the dental considerations for patients undergoing chemotherapy and cover how to address dental problems and what to consider when consulting with dentists.
-
Review Article | 2024-12-20 60
20
소화기암에서 체계적 문헌고찰과 메타분석을 활용한 의료기술 비교평가 방법
Systematic Review and Meta-analysis in Digestive Cancer Research
권소현, 손낙훈
Journal of Digestive Cancer Research 2024; 12(3): 207-215 https://doi.org/10.52927/jdcr.2024.12.3.207
Abstract : This article highlights the role of meta-analysis as a statistical method for quantitatively summarizing existing research and reconciling conflicting findings. It discusses literature search methods for meta-analysis, the selection and interpretation of statistical models, and publication bias. Meta-analysis allows for the statistical consideration of homogeneity and heterogeneity among studies. Determining homogeneity and heterogeneity is crucial for selecting the appropriate meta-analysis model. Systematic reviews and meta-analyses provide a high level of evidence on treatment efficacy, especially when they include multicenter and multinational studies. In the case of well-researched disorders such as digestive cancer, meta-analysis can be useful in generalizing findings from existing papers, draw conclusions, and evaluate related medical technologies. Furthermore, these findings can be used to propose or enhance standards of care.
-
Original Article | 2024-12-20 61
18
Association between Metabolic Factors and Gastric Cancer
Su Youn Nam
Journal of Digestive Cancer Research 2024; 12(3): 216-223 https://doi.org/10.52927/jdcr.2024.12.3.216, Oh Kyoung Kwon , Seong Woo Jeon 
Abstract : Background/Aims: We investigated sex- and stage-specific associations of body mass index (BMI), fasting glucose, and high-density lipoprotein cholesterol (HDL-C) with gastric cancer.
Methods: In total, 3,382 patients with gastric cancer and 19,609 healthy controls were enrolled. BMI was categorized into five groups. HDL-C was classified as low (< 40 and < 50 mg/ dl in males and females, respectively) and normal (≥ 40 and ≥ 50 mg/dl in males and females, respectively). Logistic regression analysis was performed to calculate odd ratios (ORs) and 95% confidence intervals (CIs).
Results: After adjustment, low BMI (OR, 1.44; 95% CI, 1.13–1.84), low HDL levels (OR, 2.28; 95% CI, 2.07–2.50), and high fasting glucose levels (OR, 2.94; 95% CI, 2.22–2.99) were associated with gastric cancer, whereas high BMI (OR, 0.61–0.81) was inversely associated with gastric cancer. In sex-specific analysis, BMI was inversely associated with gastric cancer only in males (trend: p < 0.001). Low serum HDL and high fasting glucose levels were strongly associated with gastric cancer in both males and females. The effect of high glucose content was more pronounced in females (OR, 4.02) than in males (OR, 2.58). BMI was inversely associated with both AGC (trend: p < 0.001) and EGC (trend: p = 0.001). Low serum HDL and high fasting glucose levels were strongly associated with gastric cancer in EGC and AGC.
Conclusions: The effect of BMI on gastric cancer varies by sex and stage, whereas low HDL levels are associated with gastric cancer regardless of these factors. -
Case Report | 2024-12-20 45
18
고위험 직장 위장관 기질 종양 환자에서 발생한 Imatinib 유발 폐렴의 진단과 치료
Diagnosis and Treatment of Imatinib-induced Pneumonitis in a Patient with High-risk Rectal Gastrointestinal Stromal Tumor
김성중, 이 준
Journal of Digestive Cancer Research 2024; 12(3): 224-228 https://doi.org/10.52927/jdcr.2024.12.3.224
Abstract : Imatinib is a well-established targeted therapeutic agent for gastrointestinal stromal tumors (GISTs), acting as a key tyrosine kinase inhibitor. Despite its clinical efficacy, imatinib is associated with a variety of side effects, ranging from minor issues like diarrhea and fatigue to serious complications such as hepatotoxicity, cardiotoxicity, and hematologic abnormalities that necessitate discontinuation. Notably, imatinib-induced pneumonitis, though rare, can be fatal, necessitating early detection and intervention. This side effect usually manifests as severe dyspnea, fever, and cough shortly after the start of therapy. The diagnosis requires the exclusion of other causes of pneumonia, such as infections, and is supported by imaging that reveals interstitial infiltrates in both lungs. Imatinib should be discontinued immediately, and corticosteroid therapy should be initiated. If treatment with imatinib is deemed necessary following recovery, a lower dose may be considered, but there is a high risk of recurrence. In such cases, sunitinib may be considered as an alternative treatment option. We present a case of imatinib-induced pneumonitis in a 68-year-old male patient who underwent adjuvant imatinib therapy following endoscopic resection of a high-risk rectal GIST. The purpose of this report is to review the clinical features, diagnosis, and treatment of imatinib-induced pneumonitis using a literature review.
-
Research Trend | 2024-12-20 41
25
간세포암에서 면역관문억제제와 국소치료 병합요법의 새로운 전망
Emerging Prospects for Combining Immune Checkpoint Inhibitors with Loco-regional Therapy in Hepatocellular Carcinoma
조은영1,*, 이창훈2,3,*, 김인희2,3
Journal of Digestive Cancer Research 2024; 12(3): 229-233 https://doi.org/10.52927/jdcr.2024.12.3.229 -
Education Series | 2024-12-20 45
21
Adjuvant Treatment Required during Survivorship Following Surgery and Chemotherapy for Colorectal Cancer
Jong Yoon Lee
Journal of Digestive Cancer Research 2024; 12(3): 234-236 https://doi.org/10.52927/jdcr.2024.12.3.234
Full Text
PDF
Cite
ShareJournal Info
December 20, 2024
pISSN : 2950-9394
Frequency: Triannual
Most KeyWord
?
What is Most Keyword?
- It is most registrated keyword in articles at this journal during for 2 years.
Editorial Office
- Editor-in-ChiefProf. Jie-Hyun Kim
- journal@jdcr.org
- +82-2-313-7710
- +82-2-313-7901
